![](/img/cover-not-exists.png)
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors : Results of a multicenter phase 2 trial
Andrew J. Wagner, John M. Goldberg, Steven G. DuBois, Edwin Choy, Lee Rosen, Alberto Pappo, James Geller, Ian Judson, David Hogg, Neil Senzer, Ian J. Davis, Feng Chai, Carol Waghorne, Brian Schwartz,Volume:
aop
Year:
2012
Language:
english
Pages:
1
DOI:
10.1002/cncr.27582
File:
PDF, 307 KB
english, 2012